Skip to content Skip to footer
Subscribe Now
Apellis
NEWS

Apellis Pharmaceuticals Reports the US FDA’s Approval of Empaveli for C3 Glomerulopathy and Primary IC-MPGN

Shots: The US FDA has approved Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) & primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) pts (≥12yrs.) Approval was based on P-III (VALIANT) trial assessing Empaveli (Q2W) vs PBO in C3G & primary IC-MPGN pts (≥12yrs., n=124) for 26wks. followed by 26wk. open-label period, where all pts received Empaveli Trial met…
July 30, 2025

Read more

PharmShots Interview In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy
VIEWPOINTS

PharmShots Interview: In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy

Shots: Nancy spoke about the results from the Geographic Atrophy Insights Survey (GAINS) Nancy also talked about the emotional burden on the patients and the devastating impact on independence caused by vision loss  The global survey was conducted by The Harris Poll on behalf of Apellis Pharmaceuticals to find the impact of GA which is a…
July 6, 2022

Read more

Viewpoints_Federico Grossi
VIEWPOINTS

PharmaShots Interview: Apellis’ Federico Grossi Shares Insights on the Data in GA Presented at ARVO 2021

In an interview with PharmaShots, Apellis' Chief Medical Officer, Federico Grossi shares his views on the data presented at ARVO 2021. The studies support AI analytics as a tool to distinctly measure disease activity well as the therapeutic effect in GA. Shots: Apellis presented five oral presentations from an AI collaboration with the Ophthalmic Imaging Analysis (OPTIMA)…
June 9, 2021

Read more